EKF Diagnostics Holdings plc
("EKF", the "Company")
Notice of results
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its interim results for the six months ended 30 June 2019 on Tuesday 10 September 2019.
Investor briefing
A briefing for all investors will take place on Tuesday 10 September 2019 at the Brand Exchange, 3 Birchin Lane, EC3V 9BW from 5.30pm for a 5.45pm start and will be followed by refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email ekf@walbrookpr.com
Enquiries:
|
EKF Diagnostics Holdings plc |
|
|
Christopher Mills, Non-Executive Chairman |
Tel: 029 2071 0570 |
|
Julian Baines, CEO |
|
|
Richard Evans, FD & COO |
|
|
|
|
|
N+1 Singer (Nomad & Broker) |
Tel: 020 7496 3000 |
|
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking) |
|
|
|
|
|
Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com |
|
|
Paul McManus/ Lianne Cawthorne |
Mob: 07980 541 893 / 07584 391 303 |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.